Search results
Biogen and Sage to scrap neurological disorder drug development after trial failure - ET HealthWorld...
The Economic Times· 6 hours agoLondon: Biogen and Sage Therapeutics do not plan to conduct further studies for their neurological...
Biogen, Sage tremor drug fails key trial
BioPharma Dive· 6 hours agoIn 2020, Biogen wagered more than $1 billion on two experimental drugs developed in the labs of Sage Therapeutics, a fellow Cambridge,...
Autobahn raises $100M on investor interest in neuropsych drugs
BioPharma Dive· 8 hours agoNew investors included Canaan Partners, Monograph Capital, and Insight Partners, while Autobahn’s...